The use of the chemotherapy regimen FOLFOXIRI plus Avastin has increased from 2013 to 2022 in patients with metastatic colorectal cancer, particularly in patients aged 50 years and younger. The rate ...
Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported the survival benefit among patients with left-sided tumors and the overall study population ...
The benefit obtained from Keytruda plus chemotherapy in patients with persistent, recurrent or metastatic cervical cancer occurred regardless of whether they also received Avastin. Patients with ...
The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized, placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to capecitabine-cisplatin in the ...
High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...
CHICAGO, June 6 (Reuters) - Long-term use of Swiss drugmaker Roche Holding AG's Avastin, in combination with chemotherapy, helped women with advanced ovarian cancer live longer without their cancer ...
FDA APPROVES GENENTECH’S AVASTIN (BEVACIZUMAB) PLUS CHEMOTHERAPY AS A TREATMENT FOR WOMEN WITH ADVANCED OVARIAN CANCER FOLLOWING INITIAL SURGERY – Avastin is now approved for ten distinct uses across ...
CHICAGO, Nov 18 (Reuters) - The popular cancer drug Avastin raises the risk of blood clots in the veins by a third when added to chemotherapy, U.S. researchers said on Tuesday. Sign up here. An ...
Roche Holding AG's Avastin may increase a cancer patient's risk of having a fatal reaction to treatment when it is added to chemotherapy, researchers said. Deadly side effects occurred in 2.5 percent ...
SAN ANTONIO, Texas — Adding bevacizumab (Avastin, Roche/Genentech) to chemotherapy for the treatment of triple-negative breast cancer after surgery does not significantly improve disease-free survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback